Key result
High cDPP3 before VA-ECMO is linked to ~313% higher 30-day mortality in cardiogenic shock.
Why the study?
Prognostic properties of cDPP3 had not yet been investigated in the most severe CS patients requiring VA-ECMO.
Is high cDPP3 concentration before VA-ECMO implantation associated with worse 30-day survival and organ dysfunction in patients with cardiogenic shock?
Cohort (n=47)
Is high cDPP3 concentration before VA-ECMO implantation associated with worse 30-day survival and organ dysfunction in patients with cardiogenic shock?
High cDPP3 levels before VA-ECMO implantation in cardiogenic shock patients are associated with greater organ dysfunction and significantly lower 30-day survival.
Answers are grounded in this paper and cite their sources.
High cDPP3 may flag higher-risk VA-ECMO patients; extends prior prognostic signals to severe CS but leaves clinical utility open.
Background Circulating dipeptidyl peptidase–3 (cDPP3), a protease involved in angiotensin II degradation, has demonstrated prognostic properties, including organ dysfunction and/or mortality in patients with cardiogenic shock (CS) or at risk of developing CS. However, prognostic properties of cDPP3 have not yet been investigated in the most severe CS patients requiring venoarterial extra corporeal membrane oxygenation (VA–ECMO). Method This is a post hoc analysis of the ADRECMO study, a prospective cohort of 50 patients primarily designed to investigate the association between inflammation and adrenoreceptor expression in patients with CS receiving VA-ECMO. cDPP3 measurements were performed before VA-ECMO implantation, 3–5 days later while VA-ECMO was ongoing, and before explantation. Associations between cDPP3 concentrations at the predefined timepoints and level of organ dysfunction and 30-day survival were investigated. Results Forty-seven patients were analysed. Median cDPP3 was 73 (IQR 46 – 151) ng/mL at VA-ECMO implantation decreasing to 47 (30 – 64) ng/mL at day 3 to 5 and 39 (29 – 50) ng/mL at the day of explantation (p<0.001). Patients with cDPP3 >73 ng/mL at VA-ECMO implantation exhibited, higher lactate concentrations (3.5 [2.5 – 5.9] vs. 1.9 [1.3 – 3] mmol/L, p<0.001), worse eGFR (26 [15 – 40] vs. 75 [48 – 102] mL/min/1.73m 2 , p<0.001), higher AST levels (1127 [587 – 1970] vs. 195 [50 – 646] IU/L, p<0.001) and greater norepinephrine cumulated dose (682 [326 – 2258] vs. 93 [0 – 349] μg/kg, p=0.001) compared to patients with lower cDPP3 concentrations. After adjustment for CS cause, timing of VA-ECMO implantation, and cardiac arrest before implantation, patients with high cDPP3 before implantation exhibited lower survival compared with patients with low cDPP3 (adjusted HR 4.13 [95% CI 1.55–10.98]). No significant association was observed between cDPP3 concentrations at later timepoints and 30-day survival. Conclusion In a population of CS patients on VA-ECMO, high cDPP3 measured before implantation is associated with greater severity of organ dysfunction and lower 30-day survival.
No takes yet. Share an insight, caveat, or question.
Bruno et al. (2026) conducted a cohort in Cardiogenic shock requiring VA-ECMO (n=47). High cDPP3 concentrations (>73 ng/mL) vs. Low cDPP3 concentrations was evaluated on 30-day survival (adjusted HR 4.13, 95% CI 1.55-10.98). High cDPP3 concentrations before VA-ECMO implantation in patients with cardiogenic shock were associated with lower 30-day survival.
Synapse has enriched 10 related papers. Consider them for comparative context: